Why Novartis lost its treatment dispute with Teva

In a patent revocation and infringement counterclaim action between Teva and Novartis, His Honour Judge Richard Hacon found, in a decision handed down on November 10 2022, lack of inventive step with respect to two Novartis formulation patents ( EP 2,964,202 and EP 3,124,018)

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Big Pharma

Is there a step between ‘inventive’ and ‘nonobviousness’?

12 September 2023 Despite the shared language, there are tangible differences between the US, EU and UK standards, explain Jeffrey Lewis and Stuart Knight of Foley Hoag.

Big Pharma

Novartis ‘abused’ discovery process for Zolgensma patent

23 May 2023 Two subsidiaries of the French pharma giant allege ‘wilful’ patent infringement by the Swiss-American pharma firm | Novartis ‘hid’ information in a previous lawsuit relating to spinal muscular atrophy drug used to treat young children.

Generics

Novartis vows to challenge heart drug patent loss

11 July 2023 Decision affects a patent listed in the Orange Book | Generic drug makers have so far failed to secure approval for biosimilar versions of the blockbuster drug.

More on this story

Big Pharma

Is there a step between ‘inventive’ and ‘nonobviousness’?

12 September 2023 Despite the shared language, there are tangible differences between the US, EU and UK standards, explain Jeffrey Lewis and Stuart Knight of Foley Hoag.

Big Pharma

Novartis ‘abused’ discovery process for Zolgensma patent

Generics

Novartis vows to challenge heart drug patent loss

11 July 2023 Decision affects a patent listed in the Orange Book | Generic drug makers have so far failed to secure approval for biosimilar versions of the blockbuster drug.

More on this story

Big Pharma

Is there a step between ‘inventive’ and ‘nonobviousness’?

12 September 2023 Despite the shared language, there are tangible differences between the US, EU and UK standards, explain Jeffrey Lewis and Stuart Knight of Foley Hoag.

Big Pharma

Novartis ‘abused’ discovery process for Zolgensma patent

Generics

Novartis vows to challenge heart drug patent loss

11 July 2023 Decision affects a patent listed in the Orange Book | Generic drug makers have so far failed to secure approval for biosimilar versions of the blockbuster drug.

More features

Fed Circ orders Teva to delist five patents from Orange Book

Novartis shields eye-drop patent at European Patent Office

CREATES Act unfairly tips the scales to generics

LSPN launches its first-ever US awards to celebrate life sciences leaders

Pharma giants seek closure on COVID-19 vaccine rows

Foley & Lardner adds litigation and transaction expert in New York

‘AI curious’ counsel at AZ, Novartis weigh risks and benefits

Trump’s return sparks calls for pro-patent agenda

Why Novartis lost its treatment dispute with Teva

More on this story

Editor's picks

Editor's picks

More on this story

More on this story

More features